Kathleen I. PritchardHoward A. BurrisYoshinori ItoHope S. RugoShaker DakhilGabriel N. HortobagyiMario CamponeTibor CsösziJosé BaselgaPuttisak PuttawibulMartine PiccartDaniel HengShinzaburo NoguchiVichien SrimuninnimitHugues BourgeoisAntonio Gonzalez MartinKaren OsborneAshok PanneerselvamTetiana TaranTarek SahmoudMichael GnantUniversity of TorontoSarah Cannon Research InstituteCancer Institute Hospital of Japan Foundation for Cancer ResearchUCSF Helen Diller Family Comprehensive Cancer CenterCancer Center of KansasUniversity of Texas MD Anderson Cancer CenterCentre de Recherche en CancérologieHetenyi Geza County HospitalMemorial Sloan-Kettering Cancer CenterPrince of Songkla UniversityInstitut Jules BordetUniversity of CalgaryOsaka UniversityMahidol UniversityCentre Jean BernardMD Anderson Cancer Center, MadridNovartis International AGNovartis Pharmaceuticals CorporationMedizinische Universitat Wien2018-10-192018-10-192013-01-01Clinical Breast Cancer. Vol.13, No.6 (2013), 421-43219380666152682092-s2.0-84889008307https://repository.li.mahidol.ac.th/handle/20.500.14594/31429Background Postmenopausal women with hormone receptor-positive (HR+) breast cancer in whom disease progresses or there is recurrence while taking a nonsteroidal aromatase inhibitor (NSAI) are usually treated with exemestane (EXE), but no single standard of care exists in this setting. The BOLERO-2 trial demonstrated that adding everolimus (EVE) to EXE improved progression-free survival (PFS) while maintaining quality of life when compared with EXE alone. Because many women with HR+advanced breast cancer are elderly, the tolerability profile of EVE plus EXE in this population is of interest. Patients and Methods BOLERO-2, a phase III randomized trial, compared EVE (10 mg/d) and placebo (PBO), both plus EXE (25 mg/d), in 724 postmenopausal women with HR+advanced breast cancer recurring/progressing after treatment with NSAIs. Safety and efficacy data in elderly patients are reported at 18-month median follow-up. Results Baseline disease characteristics and treatment histories among the elderly subsets (≥ 65 years, n = 275; ≥ 70 years, n = 164) were generally comparable with younger patients. The addition of EVE to EXE improved PFS regardless of age (hazard ratio, 0.59 [≥ 65 years] and 0.45 [≥ 70 years]). Adverse events (AEs) of special interest (all grades) that occurred more frequently with EVE than with PBO included stomatitis, infections, rash, pneumonitis, and hyperglycemia. Elderly EVE-treated patients had similar incidences of these AEs as did younger patients but had more on-treatment deaths. Conclusion Adding EVE to EXE offers substantially improved PFS over EXE and was generally well tolerated in elderly patients with HR+advanced breast cancer. Careful monitoring and appropriate dose reductions or interruptions for AE management are recommended during treatment with EVE in this patient population. © 2013 Elsevier Inc. All rights reserved.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyMedicineArticleSCOPUS10.1016/j.clbc.2013.08.011